Rinvoq is meant to treat adults with moderately to severely active Crohn's disease who have not had success with TNF (tumor necrosis factor) blockers. The daily pill is the first oral treatment for this group of patients.
Researchers evaluated its safety and effectiveness in two randomized trials in 857 patients with the disease. Participants received either 45 mg of Rinvoq or a placebo daily for 12 weeks.
More patients treated with the medication achieved remission than those treated with the placebo, the FDA said in a news release. Also, more people treated with the medication had improvement in intestinal inflammation, which was assessed with aThe FDA also assessed Rinvoq as a maintenance treatment, evaluating 343 patients who had responded to the 12 weeks of medication. This group received 15 mg or 30 mg once daily or a placebo for a year.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Autoinjector Pen for Humira Biosimilar, CyltezoThe FDA approved a new autoinjection option for adalimumab-adbm, a biosimilar to AbbVie's adalimumab, ahead of Cyltezo's commercial launch on July 1, 2023.
Read more »
FDA Advisory Panel Recommends RSV Vaccine for Pregnant Women'Before the pandemic, RSV was the No. 1 cause of infant hospitalization in the United States, so this is a big deal.'
Read more »
FDA Advisors Recommend Approval for First Vaccine to Protect Babies From RSVThis week, an FDA advisory panel announced their support for approval, voting unanimously on the vaccine’s effectiveness.
Read more »
The End of the FDA’s “Gay Blood Ban” Has a Puzzling, Damaging ExceptionThe agency can't quit blanket bans that target gay and bisexual men.
Read more »
Nebraska Approves Trans Surgery for Minors Ban, 12-Week Abortion BanThe Nebraska legislature approved a bill on Friday that prohibits physicians from performing abortions after 12 weeks and bans “gender-affirming care” for Nebraskan children.
Read more »